Investors Purchase Large Volume of Biogen Put Options (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) was the target of some unusual options trading activity on Wednesday. Traders purchased 5,799 put options on the stock. This represents an increase of approximately 230% compared to the average volume of 1,759 put options.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Biogen in the second quarter worth approximately $3,453,878,000. Primecap Management Co. CA purchased a new stake in shares of Biogen during the second quarter worth about $3,274,304,000. Wellington Management Group LLP grew its holdings in Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after acquiring an additional 155,828 shares in the last quarter. Amundi grew its position in shares of Biogen by 91.8% in the 2nd quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after acquiring an additional 726,004 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Biogen in the 2nd quarter valued at about $322,640,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted earnings of $2.62 per share, well above the $1.99–$2.06 analyst estimates, while revenue rose 10.6% year over year to $2.80 billion, exceeding expectations. Biogen earnings report
• Positive Sentiment: Growth Portfolio revenue increased 49% to $1.26 billion, supported by newer medicines and the first full-quarter contribution from products acquired through Apellis. Rare-disease revenue also climbed 27% to $676 million. Biogen Q3 revenue report
• Positive Sentiment: Management raised the low end of its full-year 2026 reported non-GAAP EPS outlook to $12.20–$13.00, reinforcing the view that newer products are offsetting pressure on Biogen’s established multiple sclerosis franchise. Biogen raises guidance
• Neutral Sentiment: Barclays raised its price target from $200 to $230 but maintained an “equal weight” rating. The new target remains below the recent trading level, indicating limited upside in the bank’s view. Barclays Biogen rating
• Negative Sentiment: Biogen posted a $20.6 million GAAP loss, or $0.14 per share, versus a profit in the prior-year quarter, primarily because of acquisition-related research and development charges. Investors also purchased 5,799 put options, about 230% of average daily volume, signaling increased near-term hedging or bearish speculation. Biogen GAAP loss report

Biogen Stock Down 1.9%

Shares of Biogen stock traded down $4.91 during trading on Wednesday, hitting $247.82. 925,900 shares of the stock were exchanged, compared to its average volume of 1,208,653. Biogen has a 12-month low of $138.00 and a 12-month high of $258.78. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock has a market cap of $36.62 billion, a price-to-earnings ratio of 43.95, a price-to-earnings-growth ratio of 2.99 and a beta of 0.09. The firm’s 50-day moving average price is $225.10 and its 200 day moving average price is $200.10.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter in the previous year, the business earned $4.81 earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, analysts forecast that Biogen will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BIIB shares. Oppenheimer reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. HC Wainwright lifted their price objective on Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Royal Bank Of Canada decreased their price objective on shares of Biogen from $260.00 to $256.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Wall Street Zen cut Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Citigroup lifted their price target on shares of Biogen from $200.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Biogen has a consensus rating of “Moderate Buy” and an average price target of $242.96.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.